More information: Abstract LBA 02: Concurrent chemoradiation +/- atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005 ...

Lung cancer survival rates have improved in recent ... Meds that block the PD-L1 protein can help the immune system attack cancer cells. Atezolizumab (Tecentriq) and durvalumab (Imfinzi) are ...

Genentech's atezolizumab has been granted a fast review in the US for some cases of advanced non-small cell lung cancer. The US Food and Drug Administration has granted a Priority Review for the ...

Lung cancer is the third leading cause of cancer ... Immunotherapy drugs used for extensive-stage SCLC include: Tecentriq (atezolizumab) Imfinzi (durvalumab) Imdelltra (tarlatamab) If cancer ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig ... to evaluate peluntamig in combination with the anti-PD-L1 therapy Tecentriq (atezolizumab). Dose-limiting ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity has delayed the development of novel pharmacotherapy. Now, researchers ...

The full abstract will be published online on April 25, 2025. More details about the programs for the AACR Annual Meeting 2025 are available online at AACR Annual Meeting 2025 | Meetings | AACR.

Read more about A trial of MK-7684A and chemotherapy for small cell lung cancer (KeyVibe-008) A trial of lurbinectedin and atezolizumab to improve treatment for small cell lung cancer (IMforte) This ...